Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov 28:12:10343-10360.
doi: 10.2147/OTT.S230309. eCollection 2019.

Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer

Yijia Guo  1 , Rui Cao  1 , Xiangyan Zhang  1 , Letian Huang  1 , Li Sun  1 , Jianzhu Zhao  1 , Jietao Ma  1 , Chengbo Han  1
Affiliations
Review

Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer

Yijia Guo et al. Onco Targets Ther. .

Abstract

Non-small cell lung cancer (NSCLC) is frequently associated with oncogenic driver mutations, which play an important role in carcinogenesis and cancer progression. Targeting epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase rearrangements has become standard therapy for patients with these aberrations because of the greater improvement of survival, tolerance, and quality-of-life compared to chemotherapy. Clinical trials for emerging therapies that target other less common driver genes are generating mixed results. Here, we review the literature on rare drivers in NSCLC with frequencies lower than 5% (e.g., ROS1, RET, MET, BRAF, NTRK, HER2, NRG1, FGFR1, PIK3CA, DDR2, and EGFR exon 20 insertions). In summary, targeting rare oncogenic drivers in NSCLC has achieved some success. With the development of new inhibitors that target these rare drivers, the spectrum of targeted therapy has been expanded, although acquired resistance is still an unavoidable problem.

Keywords: non-small cell lung cancer; oncogenic driver; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Key signaling pathways of oncogenic drivers in NSCLC.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nagarajan L, Louie E, Tsujimoto Y, Balduzzi PC, Huebner K, Croce CM. The human c-ros gene (ROS) is located at chromosome region 6q16—-6q22. Proc Natl Acad Sci U S A. 1986;83(17):6568–6572. doi:10.1073/pnas.83.17.6568 - DOI - PMC - PubMed
    1. Satoh H, Yoshida MC, Matsushime H, Shibuya M, Sasaki M. Regional localization of the human c-ros-1 on 6q22 and flt on 13q12. Jpn J Cancer Res. 1987;78(8):772–775. - PubMed
    1. Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta. 2009;1795(1):37–52. doi:10.1016/j.bbcan.2008.07.006 - DOI - PubMed
    1. Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist. 2013;18(7):865–875. doi:10.1634/theoncologist.2013-0095 - DOI - PMC - PubMed
    1. Charest A, Wilker EW, McLaughlin ME, et al. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res. 2006;66(15):7473–7481. doi:10.1158/0008-5472.CAN-06-1193 - DOI - PubMed